SURMOUNT-5 showed 20.2% average loss on tirzepatide versus 13.7% on semaglutide. Mounjaro brought in $8.7 billion in Q1 2026, ahead of Keytruda's $7.9 billion.
Recap by typeshit. Full story at International Business Times AU.
A comment-for-link Instagram post saying trials of semaglutide, tirzepatide and retatrutide showed up to 28% weight loss. Little detail beyond that.
Real-world records shown at EASD 2026 had 24.1% of tirzepatide users losing 15% or more in a year, versus about 9% on semaglutide, GlobalData reports.
Survey data on 3,615 US adults showed about 30% lower odds of GLP-1 use among cancer survivors, despite more heart and kidney disease. Causes remain unclear.
11:38
RMZ digs into why weight loss results on tirzepatide vary so widely, with some people losing double what others do.
The MFDS approval rests on SURPASS-CVOT, where Mounjaro matched Trulicity on heart events in 13,000+ patients but did not prove superior.
EMY covers findings suggesting GLP-1 drugs such as Wegovy could lower the risk of certain cancers. Details on which cancers are in the full story.
Loading…